Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 3

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 3
Chunk 3
---
─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  We may not have sufficient patent lifespan to effectively protect our products and business.  
 ────────────────────────────────────────────────────────────────────────────────────────────────

  Patent policy and rule changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of any issued patents.  

  If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  If we are unable to maintain effective proprietary rights for our product candidates or any future product candidates, we may not be able to compete effectively in our markets.  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Intellectual property rights of third parties could adversely affect our ability to commercialize our product candidates.                                                         
  Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.                                                      

  We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.  
  We may be subject to claims challenging the inventorship of our intellectual property.                                                 
  We may not be able to protect our intellectual property rights throughout the world.                                                   
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Risks Related to Our Business Operations

  We will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  Due to our limited resources and access to capital, we must, and have in the past decided to, prioritize development of certain product candidates over other potential candidates.  

  We may not be successful in our efforts to identify, discover or license additional product candidates.  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────

  European data collection is governed by restrictive regulations governing the collection, use, processing and cross-border transfer of personal information.                                          
  If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have